Antares Pharma (ATRS) Receives Price Target

Antares Pharma (ATRS) : Average target price received by Antares Pharma (ATRS) is $2.67 with an expected standard deviation of $0.58. The most aggressive target on the stock is $3, whereas the most downbeat target is $2. 3 financial analysts are currently covering the stock.

Antares Pharma (ATRS) : The consensus on Antares Pharma (ATRS) based on 3 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.


Antares Pharma (NASDAQ:ATRS): The stock opened at $1.21 on Thursday but the bulls could not build on the opening and the stock topped out at $1.23 for the day. The stock traded down to $1.17 during the day, due to lack of any buying support eventually closed down at $1.21 with a loss of -0.82% for the day. The stock had closed at $1.22 on the previous day. The total traded volume was 537,737 shares.

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures for itself and with partners, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. It has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It has also developed a disposable multi-dose pen injector for use with standard cartridges.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.